Who
Hamed Shahbazi
Director
Company insider
Files Form 4 as: Director, Niagen Bioscience.
In numbers
- Trades disclosed
- 6
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 9 Aug 2022
- Last trade
- 24 Jun 2026
- Last filed
- 26 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Jun 2026filed 26 Jun 2026 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —31,746 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —31,746 at $0.00 | filing |
| 24 Jun 2025filed 3 Jul 2025 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 20 Jun 2024filed 24 Jun 2024 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 15 Jun 2023filed 16 Jun 2023 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 9 Aug 2022filed 12 Aug 2022 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.